Texas A&M scientists have unlocked new potential for astatine-211, a rare and short-lived element, as a highly precise cancer-fighting isotope. Its alpha emissions destroy tumor cells while sparing ...

Scientists at St. Jude Children's Research Hospital and Northwestern University identified a previously unknown treatment ...

In a world-first trial, scientists used a one-off CRISPR gene edit to switch off a liver “fat brake” gene, slashing stubborn ...

Dangerously high levels of “bad” cholesterol and triglycerides may be reduced by gene editing, in what study researchers hope will be a “one and done” treatment.

The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.

Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the ...

In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the ...

In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

For the first time, a drug shows effectiveness in adult human brain cells — an achievement long thought impossible.

Scientists at The University of Texas at Austin have developed a revolutionary gene-editing method using bacterial retrons that can correct multiple disease-causing mutations at once. Unlike ...

Oct 24 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Friday it would acquire gene therapy developer Adverum Biotechnologies (ADVM.O), opens new tab in a deal valued at up to $261.7 million, ...